X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA NATCO PHARMA AJANTA PHARMA/
NATCO PHARMA
 
P/E (TTM) x 19.9 13.7 145.6% View Chart
P/BV x 4.6 3.9 118.0% View Chart
Dividend Yield % 0.0 1.1 -  

Financials

 AJANTA PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
NATCO PHARMA
Mar-18
AJANTA PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,8181,080 168.3%   
Low Rs1,106671 164.8%   
Sales per share (Unadj.) Rs239.5592.1 40.4%  
Earnings per share (Unadj.) Rs52.8188.4 28.0%  
Cash flow per share (Unadj.) Rs59.5206.3 28.8%  
Dividends per share (Unadj.) Rs08.25 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs230.0833.6 27.6%  
Shares outstanding (eoy) m88.7736.90 240.6%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x6.11.5 412.8%   
Avg P/E ratio x27.74.6 595.8%  
P/CF ratio (eoy) x24.64.2 579.0%  
Price / Book Value ratio x6.41.1 605.2%  
Dividend payout %04.4 0.0%   
Avg Mkt Cap Rs m129,78232,311 401.7%   
No. of employees `0006.84.8 140.7%   
Total wages/salary Rs m3,7653,256 115.6%   
Avg. sales/employee Rs Th3,128.44,522.5 69.2%   
Avg. wages/employee Rs Th554.0674.0 82.2%   
Avg. net profit/employee Rs Th689.71,439.0 47.9%   
INCOME DATA
Net Sales Rs m21,25821,848 97.3%  
Other income Rs m242404 59.8%   
Total revenues Rs m21,49922,252 96.6%   
Gross profit Rs m6,5849,284 70.9%  
Depreciation Rs m596662 90.0%   
Interest Rs m4154 2.7%   
Profit before tax Rs m6,2268,872 70.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5391,920 80.2%   
Profit after tax Rs m4,6866,952 67.4%  
Gross profit margin %31.042.5 72.9%  
Effective tax rate %24.721.6 114.2%   
Net profit margin %22.031.8 69.3%  
BALANCE SHEET DATA
Current assets Rs m12,23621,307 57.4%   
Current liabilities Rs m3,4615,920 58.5%   
Net working cap to sales %41.370.4 58.6%  
Current ratio x3.53.6 98.2%  
Inventory Days Days6073 82.2%  
Debtors Days Days84107 79.3%  
Net fixed assets Rs m11,14014,986 74.3%   
Share capital Rs m177369 47.9%   
"Free" reserves Rs m20,23730,353 66.7%   
Net worth Rs m20,41430,760 66.4%   
Long term debt Rs m100-   
Total assets Rs m24,48637,151 65.9%  
Interest coverage x1,519.458.6 2,592.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.6 147.6%   
Return on assets %19.219.1 100.1%  
Return on equity %23.022.6 101.6%  
Return on capital %30.529.3 103.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,66710,322 113.0%   
Fx outflow Rs m1,6162,978 54.2%   
Net fx Rs m10,0527,343 136.9%   
CASH FLOW
From Operations Rs m2,8544,636 61.6%  
From Investments Rs m-2,604-11,155 23.3%  
From Financial Activity Rs m-26,509 -0.0%  
Net Cashflow Rs m248-18 -1,378.3%  

Share Holding

Indian Promoters % 73.8 52.0 141.8%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 1.6 7.8 19.8%  
FIIs % 7.6 16.6 45.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 26.0 65.4%  
Shareholders   20,968 25,395 82.6%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  BIOCON LTD  UNICHEM LAB  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Finish Flat; IT and Pharma Stocks Witness Selling(Closing)

Share markets in India ended their trading session on a flattish note. Sectoral indices ended on a mixed note with stocks in the IT sector and pharma sector witnessing most of the selling pressure.

Related Views on News

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Nov 14, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS